Optics News

In this episode, Cathleen McCabe, MD, Dagny Zhu, MD, and Laura Periman, MD, chat with Kendra Hileman and Jasmine Ainetchian about women in leadership and championing other women in their careers.

NEW ORLEANS — Objectively measured accommodative amplitude increased throughout the day in children using low-dose atropine for myopia management, according a study presented at Academy ’23.

LAS VEGAS — Visus Therapeutics completed one clinical trial for Brimochol PF, a once-daily drop for presbyopia, earlier this year and is currently enrolling patients for a second trial, a company executive said at Vision Expo West.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTF with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space.

Vyluma Inc. has announced that the FDA will review its new drug application for NVK002, a preservative-free, low-dose atropine eye drop for myopia in children aged 3 to 17 years.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at the Eyecelerator 2023 with five special guests to discuss the future and developments in eye care.

A study found that more than one in four U.S. adults aged 71 years and older are visually impaired, with increasing prevalence related to older age, less education, lower income, non-white race and Hispanic ethnicity.

NovaSight announced that it is launching CureSight, its digital therapy for amblyopia, to the U.S. market this month.

We ophthalmologists are all introduced to pinhole or small-aperture optics on the first day of our residency when we are taught how to measure visual acuity and refract a patient.